An Observer-blind Study to Evaluate the Efficacy, Safety, Reactogenicity and Immunogenicity of the GSK Biologicals' Investigational Vaccine GSK3277511A When Administered to COPD Patients
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2018
At a glance
- Drugs GSK 3277511 (Primary)
- Indications Respiratory tract disorders
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 01 Dec 2017 Status changed from not yet recruiting to recruiting.
- 22 Nov 2017 Planned initiation date changed from 15 Nov 2017 to 27 Nov 2017.